Synopsis
CDK4/6 inhibitors in Breast Cancer Therapy examines the pivotal role of CDK4/6 inhibition in treating hormone receptor-positive (HR+)/HER2-negative advanced breast cancer. The book highlights FDA-approved applications of these inhibitors alongside endocrine therapy and explores ongoing research into their potential as neoadjuvant treatments. It provides insights into the drug discovery and development of CDK4/6 inhibitors, covering their molecular mechanisms, pharmacology, and clinical applications. Chapters address their use in mono and adjuvant therapies, as well as challenges in targeting, while also discussing market potential and post-marketing safety issues.
This book is a valuable resource for researchers and academics, enhancing understanding of CDK4/6 inhibitors' chemistry and therapeutic implications. By presenting detailed information on clinical trials and market formulations, it equips the audience with essential knowledge to navigate the complexities of targeted breast cancer therapies and contributes to advancing research in this critical area.
- Provides comprehensive insights into drug discovery and development processes of CDK4/6 inhibitors, detailing the molecular mechanisms and pharmacological aspects relevant to targeted breast cancer therapy
- Explores the current clinical applications of CDK4/6 inhibitors, including their use in mono and adjuvant therapies
- Discusses market potential and the post-marketing safety issues associated with CDK4/6 inhibitors
About the Authors
Dr. Pankaj Kumar Singh, Ph.D., is an Associate Professor in the Department of Pharmaceutics at the National Institute of Pharmaceutical Education and Research-Hyderabad (NIPER-Hyderabad), India. He earned his Doctorate from CSIR-Central Drug Research Institute, Lucknow. He has authored more than 130 peer-reviewed publications in high-reputation international journals and contributed to over 64 book chapters. He holds 4 granted patents and has 5 patent applications filed on the area of drug delivery. He has supervised 7 PhD students and 38 MS students, and is currently guiding 9 PhD and 6 MS students on their dissertations and research projects. His research focuses on targeted drug delivery to cancer. Dr Singh's lab is actively involved in various scientific and socially impactful projects funded by prestigious organisations, including TSCOST-DBT, CCRUM, DST, ICMR, and the Department of Pharmaceuticals, Ministry of Chemicals and Fertilisers, Government of India.
Manish K. Chourasia is the Chief Scientist in the Division of Pharmaceutics and Pharmacokinetics at CSIR Central Drug Research Institute (CDRI), Lucknow, India. He has played a significant role in advancing the field of nanoparticle-based drug delivery for breast cancer and neurodegenerative disorders, aiming to enhance the therapeutic outcome.
Neelesh Kumar Mehra is an Assistant Professor of Pharmaceutics in the Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research, Hyderabad, India. He has authored more than 140 peer-reviewed publications in high-repute international journals, and has contributed to over 50 book chapters. He holds 4 granted patents and has 5 patent applications filed on manufacturing processes and compositions to improve therapeutic efficacy for drug delivery. He has supervised 5 PhD students and 36 MS students, and is currently guiding 10 PhD and 7 MS students on their dissertations and research projects. His research focuses on the design, development, and evaluation of ophthalmic nanoemulsions, liposomes, lipid-polymer nanoparticles, carbon nanoparticles, and chitosan/PLGA-lipid nanoparticles for drug and biomolecule delivery in biomedical applications.
Dr. K. Gowthamarajan is a Professor & Head of the Department of Pharmaceutics at JSS College of Pharmacy, India. He holds a master’s (1996) and a Doctoral degree (2007) from Tamil Nadu Dr. MGR Medical University. With over 20 years in drug delivery research, he specializes in intranasal systems and personalized therapy. He has guided 50+ PG and 16 PhD students and secured various government research grants. An accomplished author with 150+ publications and 23 patents, he serves on multiple editorial boards and committees. He has received numerous awards, including the CV Raman International Fellowship.
"About this title" may belong to another edition of this title.
